Welcome to our dedicated page for Tempus AI SEC filings (Ticker: TEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tempus AI, Inc. (NASDAQ: TEM) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Tempus is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, and its filings offer insight into how it reports financial performance, manages capital, and documents material corporate events.
Investors can review Form 8-K filings where Tempus discloses items such as preliminary financial results, earnings press releases, credit agreement amendments, securities offerings, and other significant developments. For example, Tempus has used 8-K reports to furnish quarterly financial information, describe an automatic shelf registration statement and related prospectus supplement, and detail the terms of its convertible senior notes due 2030, including conversion features, redemption provisions, and associated capped call transactions.
Over time, this page will also surface Tempus’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically include segment information for its Diagnostics and Data and applications businesses, risk factor discussions, and management’s analysis of operations. In addition, users can expect access to ownership and insider transaction disclosures, such as Form 4 filings, when they are available from EDGAR.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings in clear language. Real-time updates from EDGAR help ensure that new TEM filings appear promptly, while AI-generated highlights can draw attention to important terms in credit agreements, securities offerings, or covenant changes. This combination allows readers to navigate Tempus’s regulatory history more efficiently, from capital structure details to ongoing financial reporting.
TEM submitted a Form 144 notice proposing sales of Class A Common Stock. The filing lists proposed dispositions tied to Restricted Stock Units dated 10/23/2025 (7 shares) and 04/22/2026 (1,573 shares). The filing shows exchange listing NASDAQ and a filing-related date of 05/19/2026.
TEM filed a Rule 144 notice listing proposed and recent transactions in Class A Common Stock. The filing lists Restricted Stock Units by grant date and quantity: 04/27/2022 (1,612), 04/18/2023 (549), 07/18/2023 (2,742), 05/02/2024 (731), 11/01/2024 (823) and 02/11/2026 (2,246). It also reports recent brokered sales by Andrew Polovin: 02/19/2026 — 8,143 shares for $480,856.74, and 02/20/2026 — 10,949 shares for $660,290.36, described as 10b5-1 sales.
TEM reporting person Eric Lefkofsky and affiliated entities reported sales of Class A Common Stock. The filing lists multiple dispositions on and specific dates in 2026, including sales by Eric Lefkofsky of 13,587 shares on 02/19/2026 and by Blue Media, LLC of 133,000 shares on 02/19/2026. The entries show additional sales by the same entities on and later dates through 04/28/2026.
TEM: Individual filed a Form 144 proposing a sale of $566,405.34 of Class A Common Stock. The filing lists a sale of 9,592 shares on 02/19/2026. The submission also itemizes previously issued Restricted Stock Units granted on multiple dates with discrete share counts.
Tempus AI, Inc. executive Fukushima Ryan, CEO, Data, reported two bona fide gifts of Class A Common Stock. On May 14, 2026, he transferred 62,239 shares held indirectly through his spouse and 162,239 shares held directly, both at a price of $0.00 per share. Following these gifts, he holds 211,047 shares indirectly via his spouse and 617,108 shares directly. The footnote states these were bona fide gifts for no consideration and that both he and his spouse are subject to a lock-up agreement expiring on June 21, 2026, with this gift treated as a permissible exemption under that lock-up.
Tempus AI, Inc. completed a private offering of $460.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032, using an indenture with U.S. Bank Trust Company as trustee. The notes are unsecured, carry no regular interest and mature on May 15, 2032, with special interest only in defined circumstances.
Net proceeds were approximately $441.9 million, of which Tempus repaid $307.7 million of outstanding loans under its senior secured credit facilities and spent about $31.2 million on capped call transactions, with the balance for general corporate purposes. The initial conversion rate is 14.4388 shares per $1,000 principal (conversion price about $69.26, a 40% premium), and a maximum of 9,298,532 shares may be issuable based on a higher maximum conversion rate. Capped call transactions, struck at an initial cap price of $98.94, are intended to reduce dilution or offset cash paid above principal on conversion.
Tempus AI, Inc. Schedule 13G/A amendment shows Baillie Gifford & Co. beneficially owned 8,649,356 shares of Tempus AI common stock, equal to 4.98% of the class as of 03/31/2026. The filing lists 8,615,766 shares as sole voting power and 8,649,356 as sole dispositive power. The filing is signed by Grant Meikle on 05/07/2026.
Schoenherr Thomas Edward reported acquisition or exercise transactions in this Form 4 filing.
Tempus AI, Inc. executive Thomas Edward Schoenherr, CEO of Diagnostics, received an equity award reported as 13,642 shares of Class A Common Stock. This represents two restricted stock unit grants: 3,642 RSUs are fully vested, and 10,000 RSUs will vest in eight equal quarterly installments starting on November 15, 2026. Following this grant, Schoenherr directly holds 108,609 shares of Class A Common Stock. The transaction reflects a compensation-related share award rather than an open-market purchase or sale.
Rogers James William reported acquisition or exercise transactions in this Form 4 filing.
Tempus AI, Inc. reported that its Chief Financial Officer, James William Rogers, received a grant of 10,000 shares of Class A Common Stock in the form of restricted stock units. The award was granted at no cash cost to him and is part of his compensation. The RSUs vest in eight equal quarterly installments beginning on November 15, 2026. Following this grant, he holds 137,248 shares of Class A Common Stock directly.
Polovin Andrew reported acquisition or exercise transactions in this Form 4 filing.
Tempus AI, Inc. reported that EVP and Chief Legal Officer Andrew Polovin received a grant of 10,000 shares of Class A Common Stock in the form of restricted stock units. The RSUs vest in eight equal quarterly installments starting on November 15, 2026. After this award, he directly holds 136,918 shares.